Company press releases

Displaying 101 - 128 of 128 results
Released Company Title Industry Topic
05 Sep 2022
19:00 CEST 		ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
05 Sep 2022
16:30 CEST 		ULTIMOVACS Ultimovacs ASA: Share capital increase related to exercise of options 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
22 Aug 2022
17:00 CEST 		ULTIMOVACS Ultimovacs Strengthens IP Portfolio with the United States Patent and Trademark Office (USPTO) Notice of Allowance on UV1 Method Patent 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
19 Aug 2022
08:00 CEST 		ULTIMOVACS Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update 20103010 Biotechnology Half yearly financial reports and audit reports/limited reviews
18 Aug 2022
08:00 CEST 		ULTIMOVACS Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
12 Aug 2022
08:00 CEST 		ULTIMOVACS Ultimovacs ASA: Invitation to second quarter 2022 results webcast presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
30 Jun 2022
13:20 CEST 		ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
30 Jun 2022
08:00 CEST 		ULTIMOVACS Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
20 Jun 2022
08:00 CEST 		ULTIMOVACS Ultimovacs' UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
25 May 2022
18:45 CEST 		ULTIMOVACS Ultimovacs' Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
12 May 2022
08:00 CEST 		ULTIMOVACS Ultimovacs ASA: First quarter 2022 result presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
10 May 2022
08:00 CEST 		ULTIMOVACS Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
05 May 2022
08:00 CEST 		ULTIMOVACS Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
22 Apr 2022
08:00 CEST 		ULTIMOVACS Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
21 Apr 2022
16:30 CEST 		ULTIMOVACS Ultimovacs ASA - Share Option Program 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
21 Apr 2022
11:14 CEST 		ULTIMOVACS Ultimovacs ASA - Annual General Meeting held on 21 April 2022 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
08 Apr 2022
19:00 CEST 		ULTIMOVACS Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
08 Apr 2022
16:30 CEST 		ULTIMOVACS Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting 20103010 Biotechnology Total number of voting rights and capital
30 Mar 2022
11:00 CEST 		ULTIMOVACS Ultimovacs to host Investor Days 2022: Meet the Team 20103010 Biotechnology Non-regulatory press releases
25 Mar 2022
08:47 CET 		ULTIMOVACS Correction: Ultimovacs ASA: Annual Report 2021 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
25 Mar 2022
07:50 CET 		ULTIMOVACS Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
25 Mar 2022
07:30 CET 		ULTIMOVACS Ultimovacs ASA: Annual Report 2021 20103010 Biotechnology Annual financial and audit Reports
21 Mar 2022
08:00 CET 		ULTIMOVACS Ultimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of Melanoma 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
09 Mar 2022
16:30 CET 		ULTIMOVACS Ultimovacs to Present Preclinical Data on TET Platform at American Association for Cancer Research (AACR) 2022 Annual Meeting 20103010 Biotechnology Non-regulatory press releases
17 Feb 2022
13:18 CET 		ULTIMOVACS Ultimovacs ASA: Mandatory notification of trade by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
17 Feb 2022
08:00 CET 		ULTIMOVACS Ultimovacs ASA: Fourth quarter 2021 result presentation 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
10 Feb 2022
08:00 CET 		ULTIMOVACS Ultimovacs ASA: Invitation to fourth quarter 2021 results webcast presentation 20103010 Biotechnology Non-regulatory press releases
03 Feb 2022
08:00 CET 		ULTIMOVACS Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State